VolitionRx Limited, a multi-national epigenetics company, develops blood tests to help detect and monitor a range of cancers, and diseases associated with NETosis in the United States, Europe, and Asia. The company offers Nu.Q Vet, a cancer screening test for dogs and other animals; Nu.Q Nets, detects diseases associated with NETosis, such as sepsis; Nu.Q Discover, a solution to profiling nucleosomes. It also provides Nu.Q Cancer for predicting treatment response, monitoring treatment response and disease progression, and amending a patient's cancer treatment regimen; and Capture-PCR and Capture-Seq, which are isolating and capturing circulating tumor-derived DNA from plasma samples for early cancer detection. VolitionRx Limited is headquartered in Henderson, Nevada.…
VolitionRx Highlights a Transformational Year: Clinical Validation, Commercial Partnerships, and Potential Upcoming Milestones
VolitionRx (NYSEAMERICAN: VNRX) is listed on NYSE American, where its shares trade in USD. It belongs to the Medical Devices industry, part of the Healthcare sector, and reports about 57 employees.
The shares were at 0.1621 USD on 20 November 2026, down 97.9% over 52 weeks. Its 52-week range is 0.1555 USD to 8.200 USD: the price is 98.0% below the high and 4.2% above the low.
Its market capitalisation is 5.85M USD.
VolitionRx reports return on equity of 68.2% and revenue down 2.0% year over year.
Its debt exceeds its cash by 8.62M USD. Its Piotroski F-score is 2 out of 9, a weak reading of its financial health. The next earnings report is expected on 31 March 2027.